| 70.7 0.86 (1.23%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 82.64  |
1-year : | 96.53 |
| Resists | First : | 70.76 |
Second : | 82.64 |
| Pivot price | 65.55 |
|||
| Supports | First : | 55.51 |
Second : | 46.09 |
| MAs | MA(5) : | 69.99 |
MA(20) : | 61.42 |
| MA(100) : | 44.65 |
MA(250) : | 37.13 |
|
| MACD | MACD : | 6.2  |
Signal : | 5.8 |
| %K %D | K(14,3) : | 98.4 |
D(3) : | 97.9 |
| RSI | RSI(14): 80.4 |
|||
| 52-week | High : | 70.76 | Low : | 21.51 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RNA ] has closed below upper band by 35.2%. Bollinger Bands are 177% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 70.82 - 71.32 | 71.32 - 71.71 |
| Low: | 68.9 - 69.44 | 69.44 - 69.85 |
| Close: | 70.01 - 70.83 | 70.83 - 71.47 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Tue, 11 Nov 2025
Should Doubling of Net Losses in Q3 Require Action From Avidity Biosciences (RNA) Investors? - simplywall.st
Tue, 11 Nov 2025
Decoding Avidity Biosciences Inc (RNA): A Strategic SWOT Insight - GuruFocus
Mon, 10 Nov 2025
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates - Nasdaq
Sun, 02 Nov 2025
Exploring Avidity Biosciences (RNA) Valuation Following Recent Share Price Surge - Yahoo Finance
Sun, 02 Nov 2025
Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger - Yahoo Finance
Thu, 30 Oct 2025
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 146 (M) |
| Held by Insiders | 1.0783e+008 (%) |
| Held by Institutions | 4.5 (%) |
| Shares Short | 22,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.1874e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 448.7 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | 1.073e+007 % |
| Gross Profit (p.s.) | 90.82 |
| Sales Per Share | -38.93 |
| EBITDA (p.s.) | -4.12072e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -490 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.82 |
| Price to Cash Flow | 6.94 |
| Dividend | 0 |
| Forward Dividend | 2.003e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|